## Jeehoon Kang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6739549/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet, The, 2021, 397, 2487-2496.	6.3	162
2	CD82/KAl1 Maintains the Dormancy of Long-Term Hematopoietic Stem Cells through Interaction with DARC-Expressing Macrophages. Cell Stem Cell, 2016, 18, 508-521.	5.2	130
3	Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. Lancet, The, 2020, 396, 1079-1089.	6.3	125
4	Racial Differences in Ischaemia/Bleeding Risk Trade-Off during Anti-Platelet Therapy: Individual Patient Level Landmark Meta-Analysis from Seven RCTs. Thrombosis and Haemostasis, 2019, 119, 149-162.	1.8	107
5	Comparison Among Drug-Eluting Balloon, Drug-Eluting Stent, and PlainÂBalloon Angioplasty for the Treatment of In-Stent Restenosis. JACC: Cardiovascular Interventions, 2015, 8, 382-394.	1.1	97
6	Chronic Kidney Disease in the Second-Generation Drug-Eluting Stent Era. JACC: Cardiovascular Interventions, 2016, 9, 2097-2109.	1.1	61
7	The Evolving Concept of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: Focus on Unique Feature of East Asian and "Asian Paradox― Korean Circulation Journal, 2018, 48, 537.	0.7	52
8	Third-Generation P2Y12 Inhibitors in East Asian Acute Myocardial Infarction Patients: A Nationwide Prospective Multicentre Study. Thrombosis and Haemostasis, 2018, 118, 591-600.	1.8	50
9	Focused Update of 2016 Korean Society of Heart Failure Guidelines for the Management of Chronic Heart Failure. International Journal of Heart Failure, 2019, 1, 4.	0.9	45
10	Differential Prognostic Effect Between First- and Second-Generation Drug-Eluting Stents in Coronary Bifurcation Lesions. JACC: Cardiovascular Interventions, 2015, 8, 1318-1331.	1.1	36
11	Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention. Heart, 2012, 98, 1366-1372.	1.2	34
12	The impact of residual coronary lesions on clinical outcomes after percutaneous coronary intervention: Residual SYNTAX score after percutaneous coronary intervention in patients from the Efficacy of Xience/Promus versus Cypher in rEducing Late Loss after stENTing (EXCELLENT) registry. American Heart Journal, 2014, 167, 384-392.e5.	1.2	34
13	Dual Antiplatelet Therapy Duration Determines Outcome After 2- But Not 1-Stent Strategy in Left Main Bifurcation Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 2453-2463.	1.1	33
14	Durable Polymer Versus Biodegradable Polymer Drug-Eluting Stents After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome. Circulation, 2021, 143, 1081-1091.	1.6	33
15	Predictors and Prognostic Value of Worsening Renal Function During Admission in HFpEF Versus HFrEF: Data From the KorAHF (Korean Acute Heart Failure) Registry. Journal of the American Heart Association, 2018, 7, .	1.6	32
16	The effects of erythropoiesis stimulating therapy for anemia in chronic heart failure: A meta-analysis of randomized clinical trials. International Journal of Cardiology, 2016, 218, 12-22.	0.8	28
17	The efficacy and safety of mechanical hemodynamic support in patients undergoing high-risk percutaneous coronary intervention with or without cardiogenic shock: Bayesian approach network meta-analysis of 13 randomized controlled trials. International Journal of Cardiology, 2015, 184, 36-46.	0.8	25
18	Involvement of miR-34c in high glucose-insulted mesenchymal stem cells leads to inefficient therapeutic effect on myocardial infarction. Cellular Signalling, 2015, 27, 2241-2251.	1.7	25

Jeehoon Kang

#	Article	IF	CITATIONS
19	Human Podoplanin-positive Monocytes and Platelets Enhance Lymphangiogenesis Through the Activation of the Podoplanin/CLEC-2 Axis. Molecular Therapy, 2014, 22, 1518-1529.	3.7	22
20	Increased epicardial adipose tissue thickness is a predictor of new-onset diabetes mellitus in patients with coronary artery disease treated with high-intensity statins. Cardiovascular Diabetology, 2018, 17, 10.	2.7	22
21	Temporal trends in prevalence and antithrombotic treatment among Asians with atrial fibrillation undergoing percutaneous coronary intervention: A nationwide Korean population-based study. PLoS ONE, 2019, 14, e0209593.	1.1	22
22	Intravascular Ultrasound and Angiographic Predictors of In-Stent Restenosis of Chronic Total Occlusion Lesions. PLoS ONE, 2015, 10, e0140421.	1.1	20
23	Sarcopenia Index as a Predictor of Clinical Outcomes in Older Patients with Coronary Artery Disease. Journal of Clinical Medicine, 2020, 9, 3121.	1.0	20
24	Usefulness of the SYNTAX and Clinical SYNTAX Scores in Predicting Clinical Outcome After Unrestricted Use of Sirolimus- and Everolimus-Eluting Stents. Circulation Journal, 2013, 77, 2912-2921.	0.7	19
25	Erythropoietin priming improves the vasculogenic potential of G-CSF mobilized human peripheral blood mononuclear cells. Cardiovascular Research, 2014, 104, 171-182.	1.8	19
26	Activated platelet supernatant can augment the angiogenic potential of human peripheral blood stem cells mobilized from bone marrow by G-CSF. Journal of Molecular and Cellular Cardiology, 2014, 75, 64-75.	0.9	16
27	Development and Validation of an Ischemic and Bleeding Risk Evaluation Tool in East Asian Patients Receiving Percutaneous Coronary Intervention. Thrombosis and Haemostasis, 2019, 119, 1182-1193.	1.8	16
28	Usefulness of the Baseline Syntax Score to Predict 3-Year Outcome After Complete Revascularization by Percutaneous Coronary Intervention. American Journal of Cardiology, 2016, 118, 641-646.	0.7	15
29	Comparison of Fractional FLow Reserve And Intravascular ultrasound-guided Intervention Strategy for Clinical OUtcomes in Patients with InteRmediate Stenosis (FLAVOUR): Rationale and design of a randomized clinical trial. American Heart Journal, 2018, 199, 7-12.	1.2	14
30	Characterization of Post-Translational Modifications to Calsequestrins of Cardiac and Skeletal Muscle. International Journal of Molecular Sciences, 2016, 17, 1539.	1.8	13
31	Bioresorbable Vascular Scaffolds ― Are We Facing a Time of Crisis or One of Breakthrough? ―. Circulation Journal, 2017, 81, 1065-1074.	0.7	13
32	Practical guidance for P2Y12 inhibitors in acute myocardial infarction undergoing percutaneous coronary intervention. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 112-124.	1.4	13
33	Relative Impact of Clinical Risk Versus Procedural Risk on Clinical Outcomes After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2021, 14, e009642.	1.4	13
34	Ethnic Differences in Oral Antithrombotic Therapy. Korean Circulation Journal, 2020, 50, 645.	0.7	13
35	The Predictors of Target Lesion Revascularization and Rate of In-Stent Restenosis in the Second-Generation Drug-Eluting Stent Era. Journal of Interventional Cardiology, 2019, 2019, 1-13. 	0.5	12
36	Endothelial function estimated by digital reactive hyperemia in patients with atherosclerotic risk factors or coronary artery disease. Heart and Vessels, 2018, 33, 706-712	0.5	11

JEEHOON KANG

#	Article	IF	CITATIONS
37	Efficacy and Safety of Long-Term and Short-Term Dual Antiplatelet Therapy: A Meta-Analysis of Comparison between Asians and Non-Asians. Journal of Clinical Medicine, 2020, 9, 652.	1.0	10
38	Left Ventricular Ejection Fraction 1 Year After Acute Myocardial Infarction Identifies the Benefits of the Long-Term Use of β-Blockers. Circulation: Cardiovascular Interventions, 2021, 14, e010159.	1.4	10
39	Impact of Non-Vitamin K Antagonist Oral Anticoagulants on the Change of Antithrombotic Regimens in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Korean Circulation Journal, 2021, 51, 409.	0.7	10
40	Better Prognosis After Complete Revascularization Using Contemporary Coronary Stents in Patients With Chronic Kidney Disease. Circulation: Cardiovascular Interventions, 2019, 12, e007907.	1.4	9
41	Relation between functional coronary artery stenosis and graft occlusion after coronary artery bypass grafting. Journal of Thoracic and Cardiovascular Surgery, 2021, 161, 1010-1018.e1.	0.4	9
42	Prasugrel Dose De-escalation Therapy After Complex Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome. JAMA Cardiology, 2022, 7, 418.	3.0	9
43	Clinical and Computed Tomography Angiographic Predictors of Coronary Lesions That Later Progressed to ChronicÂTotal Occlusion. JACC: Cardiovascular Imaging, 2019, 12, 2196-2206.	2.3	8
44	Procedural optimization of <scp>drugâ€coated</scp> balloons in the treatment of coronary artery disease. Catheterization and Cardiovascular Interventions, 2021, 98, E43-E52.	0.7	8
45	Benefit of Extended Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients Treated with Drug Eluting Stents for Coronary Bifurcation Lesions (from the BIFURCAT Registry). American Journal of Cardiology, 2021, 156, 16-23.	0.7	8
46	SYNTAX Score and SYNTAX Score II Can Predict the Clinical Outcomes of Patients with Left Main and/or 3-Vessel Disease Undergoing Percutaneous Coronary Intervention in the Contemporary Cobalt-Chromium Everolimus-Eluting Stent Era. Korean Circulation Journal, 2020, 50, 22.	0.7	8
47	The Effect of Admission at Weekends on Clinical Outcomes in Patients with Non-ST-segment Elevation Acute Coronary Syndrome and Its Contributing Factors. Journal of Korean Medical Science, 2015, 30, 414.	1.1	7
48	Evolution of nonculprit coronary atherosclerotic plaques assessed by serial virtual histology intravascular ultrasound in patients with ST-segment elevation myocardial infarction and chronic total occlusion. Coronary Artery Disease, 2016, 27, 650-657.	0.3	7
49	Antithrombotic Therapy in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention During 2-Year Follow-Up, from a Nationwide Population Study. American Journal of Cardiology, 2019, 123, 1921-1926.	0.7	7
50	Safety and Efficacy of Second-Generation Drug-Eluting Stents in Real-World Practice: Insights from the Multicenter Grand-DES Registry. Journal of Interventional Cardiology, 2020, 2020, 1-9.	0.5	7
51	Complete Revascularization of Multivessel Coronary Artery Disease Does Not Improve Clinical Outcome in ST-Segment Elevation Myocardial Infarction Patients with Reduced Left Ventricular Ejection Fraction. Journal of Clinical Medicine, 2020, 9, 232.	1.0	7
52	Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI. Korean Circulation Journal, 2022, 52, 304.	0.7	7
53	Effects of Widespread Inotrope Use in Acute Heart Failure Patients. Journal of Clinical Medicine, 2018, 7, 368.	1.0	6
54	Congenital heart disease at Laos Children's Hospital: Two year experience. Pediatrics International, 2017, 59, 271-279.	0.2	5

JEEHOON KANG

#	Article	IF	CITATIONS
55	The natural course of nonculprit coronary artery lesions; analysis by serial quantitative coronary angiography. BMC Cardiovascular Disorders, 2018, 18, 130.	0.7	5
56	Optimal Oversizing Index Depending on Valve Type and Leakage-Proof Function for Preventing Paravalvular Leakage after Transcatheter Aortic Valve Implantation. Journal of Clinical Medicine, 2020, 9, 3936.	1.0	5
57	Immediate Compared With Delayed Percutaneous Coronary Intervention for Patients With ST-Segment–Elevation Myocardial Infarction Presenting ≥12 Hours After Symptom Onset Is Not Associated With Improved Clinical Outcome. Circulation: Cardiovascular Interventions, 2021, 14, e009863.	1.4	5
58	Comparison of 2-Stenting Strategies Depending on Sequence or Technique for Bifurcation Lesions in the Second-Generation Drug-Eluting Stent Era ― Analysis From the COBIS (Coronary Bifurcation) Tj ETQqO	0 0og8T /(	Overlock 10 Ti
59	Comparison of early clinical outcomes between dual antiplatelet therapy and triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. PLoS ONE, 2022, 17, e0264538.	1.1	5
60	Longitudinal Patterns in Antithrombotic Therapy in Patients with Atrial Fibrillation after Percutaneous Coronary Intervention in the Non-Vitamin K Oral Anticoagulant Era: A Nationwide Population-Based Study. Journal of Clinical Medicine, 2021, 10, 1505.	1.0	4
61	De-escalation of Prasugrel Results in Higher Percentage of Patients within Optimal Range of Platelet Reactivity: Analysis from the HOST-REDUCE-POLYTECH-ACS Trial. Thrombosis and Haemostasis, 2022, 122, 160-162.	1.8	4
62	Incidence and Predictors of Stent Thrombosis in Patients Treated with Stents for Coronary Bifurcation Narrowing (From the BIFURCAT Registry). American Journal of Cardiology, 2021, 156, 24-31.	0.7	4
63	Impact of Left Ventricular Ejection Fraction on Procedural and Long-Term Outcomes of Bifurcation Percutaneous Coronary Intervention. American Journal of Cardiology, 2022, 172, 18-25.	0.7	4
64	Priming mobilized peripheral blood mononuclear cells with the "activated platelet supernatant― enhances the efficacy of cell therapy for myocardial infarction of rats. Cardiovascular Therapeutics, 2016, 34, 245-253.	1.1	3
65	Optimal Dose and Type of β-blockers in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2020, 137, 12-19.	0.7	3
66	Safety and Efficacy of Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Myocardial Infarction in the Presence of Intracoronary Thrombus: An Analysis From the Grand Drug-eluting Stent Registry. Clinical Therapeutics, 2020, 42, 954-958.e6.	1.1	3
67	Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: a Meta-Analysis. Journal of Lipid and Atherosclerosis, 2021, 10, 210.	1.1	3
68	Long-Term Comparison of Platinum Chromium Everolimus-Eluting Stent vs. Cobalt Chromium Zotarolimus-Eluting Stent ― 3-Year Outcomes From the HOST–ASSURE Randomized Clinical Trial ―. Circulation Journal, 2019, 83, 1489-1497.	0.7	2
69	Impact of Intensive Glucose Control in Patients with Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: 3-Year Clinical Outcomes. Journal of Clinical Medicine, 2020, 9, 2464.	1.0	2
70	Sex-related impact on clinical outcomes of patients treated with drug-eluting stents according to clinical presentation: Patient-level pooled analysis from the GRAND-DES registry. Cardiology Journal, 2021, , .	0.5	2
71	Time Course and Risk Factors of New-Onset Complete Atrioventricular Block After Transcatheter Aortic Valve Implantation. International Heart Journal, 2021, 62, 988-996.	0.5	2
72	Outcomes in relation to antithrombotic therapy among patients with atrial fibrillation after percutaneous coronary intervention. PLoS ONE, 2020, 15, e0240161.	1.1	2

Jeehoon Kang

#	Article	IF	CITATIONS
73	Correction to: "Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: A Meta-Analysisâ€# Journal of Lipid and Atherosclerosis, 2022, 11, 89.	1.1	2
74	The Clinical Impact of β-Blocker Therapy on Patients With Chronic Coronary Artery Disease After Percutaneous Coronary Intervention. Korean Circulation Journal, 2022, 52, 544.	0.7	2
75	Angiographic complete revascularization versus incomplete revascularization in patients with diabetes mellitus. Cardiovascular Diabetology, 2022, 21, 56.	2.7	2
76	Intractable right coronary artery spasm in the early postoperative period after heart transplantation: a case report. Korean Journal of Transplantation, 2022, 36, 154-158.	0.0	2
77	Strategy to Prime the Host and Cells to Augment Therapeutic Efficacy of Progenitor Cells for Patients with Myocardial Infarction. Frontiers in Cardiovascular Medicine, 2016, 3, 46.	1.1	1
78	The validation of the dual antiplatelet therapy score in East Asians receiving percutaneous coronary intervention with exclusively second generation drugâ€eluting stents. Catheterization and Cardiovascular Interventions, 2021, 98, E332-E341.	0.7	1
79	Siblings With Familial Dwarfism Presenting With Acute Myocardial Infarction at Adolescence. JACC: Case Reports, 2021, 3, 795-800.	0.3	1
80	Renin-Angiotensin System Blockade in Acute Myocardial Infarction: Is There a Winner?. Korean Circulation Journal, 2020, 50, 995.	0.7	1
81	Association of Side-Branch Treatment and Patient Factors in Left Anterior Descending Artery True Bifurcation Lesions: Analysis from the GRAND-DES Pooled Registry. Journal of Interventional Cardiology, 2020, 2020, 1-9.	0.5	1
82	Impact of Anticoagulation on Coronary Flow in Patients With Non-ST Elevation Acute Coronary Syndrome. Clinical and Applied Thrombosis/Hemostasis, 2015, 21, 48-57.	0.7	0
83	How far have we come with bioresorbable vascular scaffolds, and where should we go?. Cardiovascular Diagnosis and Therapy, 2017, 7, S86-S90.	0.7	0
84	Where Are the Secrets of Increased Thrombosis and Aneurysm Formation With the Current Bioresorbable Vascular Scaffolds Hidden? ― Reply ―. Circulation Journal, 2018, 82, 609-610.	0.7	0
85	Worsening Renal Function during Acute Decompensated Heart Failure: A Bad Signal Never to Ignore. International Journal of Heart Failure, 2021, 3, 121.	0.9	0
86	Percutaneous Treatment of Unprotected Left Main Disease With Thin-Strut Durable-Polymer or Early Generation Thicker-Strutted and Coated Bioabsorbable-Polymer Drug-Eluting Stents in a Large-Scale Registry. Cardiovascular Revascularization Medicine, 2021, 32, 43-49.	0.3	0
87	Bioresorbable Vascular Scaffolds: Is the Light Fading at the End of the Tunnel? ― Reply ―. Circulation Journal, 2018, 82, 2928.	0.7	0
88	Still a Long Way to Go in Treating Cardiogenic Shock in Acute Myocardial Infarction. Circulation Journal, 2020, 84, 1461-1463.	0.7	0
89	Aspirin versus clopidogrel after percutaneous coronary intervention – Authors' reply. Lancet, The, 2021, 398, 1685-1686.	6.3	0
90	Impact of Systemic Inflammatory Response Syndrome on Clinical, Echocardiographic, and Computed Tomographic Outcomes Among Patients Undergoing Transcatheter Aortic Valve Implantation. Frontiers in Cardiovascular Medicine, 2021, 8, 746774.	1.1	0

#	Article	IF	CITATIONS
91	Modifiable Risk Factors Should Be Modified Earlier to Prevent Cardiovascular Disease. Cardiometabolic Syndrome Journal, 2022, 2, 47.	1.0	0